Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab

摘要

A combination of (a) first liposomes stably associated with at least one water soluble camptothecin; and (b) a targeted anti-angiogenic antitumor agent which is a compound that decreases or inhibits the activity of an epidermal growth factor family (EGFR) receptor tyrosine kinase or that inhibits the activity of a vascular endothelial growth (VEGF) or that binds to VEGF for use in treating cancer in a subject.